Streetbeat News

Price Targets

HCP

Truist Securities analyst Miller Jump has maintained a Buy rating on HashiCorp (NASDAQ: HCP) but has reduced the price target from $34 to $27.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:58 pm

CIEN

B. Riley Securities analyst Dave Kang has reaffirmed a Buy rating on Ciena (NYSE:CIEN) and increased the price target from $67 to $68, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:57 pm

GLD

VanEck forecasts significant growth in the cryptocurrency market for 2024, including a record inflow of over $2.4 billion into Bitcoin ETFs, a new high for Bitcoin's price in Q4 2024, Binance losing its top spot in spot trading, and stablecoins reaching a market cap of over $200 billion. The firm compares potential Bitcoin ETF inflows to historical data from the SPDR Gold Trust ETF, considering the increased money supply. The Bitcoin halving event in April 2024 is expected to lead to market consolidation and a subsequent price rally. Despite Ethereum's expected outperformance of major tech stocks, it is not predicted to surpass Bitcoin in market value. Layer-2 solutions for Ethereum are anticipated to dominate post-EIP-4844.

Portfolio Pulse from Murtuza Merchant

December 08, 2023 | 4:56 pm

LULU

Truist Securities analyst Scot Ciccarelli has reaffirmed a Buy rating on Lululemon Athletica (NASDAQ:LULU) and increased the price target from $500 to $527.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:55 pm

RDNT

Truist Securities analyst David Macdonald has reaffirmed a Buy rating on RadNet (NASDAQ:RDNT) and increased the price target from $40 to $42.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:53 pm

BLUE

Bluebird Bio, Inc. (NASDAQ:BLUE) stock is trading higher after Morgan Stanley upgraded the stock from Underweight to Equal-Weight and increased the price target from $3 to $7. The upgrade is in anticipation of an FDA decision on the company's drug lovo-cel for sickle cell disease by December 20. Morgan Stanley expects the stock to rise as the decision date approaches and believes in the potential of Bluebird Bio's other treatments, Skysona and Zynteglo, in the long term. The stock has a high short interest of 23.16%.

Portfolio Pulse from Erica Kollmann

December 08, 2023 | 4:53 pm

BLUE

Bluebird Bio's stock (BLUE) is trading higher following an upgrade by Morgan Stanley from Underweight to Equal-Weight and an increase in the price target from $3 to $7.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:50 pm

OMI

UBS analyst Kevin Caliendo has reaffirmed a Buy rating on Owens & Minor (NYSE:OMI) and increased the price target from $22 to $28, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:42 pm

OXY

JP Morgan analyst John Royall has maintained a Neutral rating on Occidental Petroleum (NYSE:OXY) but has lowered the price target from $78 to $73.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:40 pm

COP

JP Morgan analyst Phil Gresh has maintained a Neutral rating on ConocoPhillips (NYSE:COP) but has reduced the price target from $153 to $141.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 4:34 pm